Annovis Bio Newsroom

Merck's (MRK) New Pneumococcal Jab Capvaxive Gets CDC Panel Vote

Yahoo FinanceJun 28 19:28

Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap

Annovis BioJun 27 12:00

Express News | Annovis Bio Inc: Files Patent for New Composition of Matter for Buntanetap

BreakingsJun 26 20:01

Annovis Bio Files Patent for New Composition of Matter for Buntanetap

Annovis BioJun 26 12:00

Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson's Disease Data

Annovis BioJun 25 12:00

Annovis Bio Highlights New Alzheimer's Data at the Alzheimer's Association International Conference 2024

Annovis BioJun 18 12:00

Maxim Group Maintains Annovis Bio(ANVS.US) With Hold Rating

Maxim Group analyst Jason McCarthy maintains $Annovis Bio(ANVS.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 29.1% and a total average return of -16.8% over the

Futu NewsJun 15 01:31 · Ratings

HC Wainwright & Co. Reiterates Buy on Annovis Bio, Maintains $23 Price Target

BenzingaJun 12 18:46

H.C. Wainwright Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $23

H.C. Wainwright analyst Ram Selvaraju maintains $Annovis Bio(ANVS.US)$ with a buy rating, and maintains the target price at $23.According to TipRanks data, the analyst has a success rate of 36.8% and

Futu NewsJun 12 18:31 · Ratings

Annovis Bio Stock Down 6%

RTTNewsJun 11 22:43

Annovis Bio's Recent Phase II/III Alzheimer's Study Of Buntanetap, Showed Statistically Significant Efficacy And Safety In Both Carriers And Non-Carriers Of Apolipoprotein E4, A Genetic Cause Of AD

BenzingaJun 11 20:08

Express News | Annovis Bio Inc: Annovis Bio Is Planning an 18-Month Phase III Trial Focusing on Biomarker-Positive Early Ad Patients

BreakingsJun 11 20:06

Express News | Annovis Bio’s Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients

BreakingsJun 11 20:05

Annovis Bio's Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients

Annovis BioJun 11 12:00

Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast

Annovis BioJun 5 12:00

Annovis Bio Initiated at Buy by Rodman & Renshaw

Dow JonesJun 5 01:02

Rodman & Renshaw Initiates Coverage On Annovis Bio With Buy Rating, Announces Price Target of $67

Analyst UpgradesJun 5 00:51

12 Health Care Stocks Moving In Friday's Intraday Session

BenzingaJun 1 00:31

Peering Into Annovis Bio's Recent Short Interest

BenzingaMay 30 00:00

Annovis Announces New Publication in a Peer-Reviewed Journal

Annovis BioMay 21 12:00